NO317730B1 - Fremgangsmate for fremstilling av dimerisk, biologisk aktivt TGF-beta-lignende protein - Google Patents

Fremgangsmate for fremstilling av dimerisk, biologisk aktivt TGF-beta-lignende protein Download PDF

Info

Publication number: NO317730B1
Authority: NO; Norway
Prior art keywords: tgf; protein; buffer; concentration; dimeric
Prior art date: 1994-07-25

Application number

NO19970326A

Other languages

English (en)

Norwegian (no)

Other versions

NO970326D0 (no

NO970326L (no

Inventor

Nico Cerletti

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-25

Filing date

1997-01-24

Publication date

2004-12-13

1997-01-24 Application filed by Novartis Ag filed Critical Novartis Ag

1997-01-24 Publication of NO970326D0 publication Critical patent/NO970326D0/no

1997-01-24 Publication of NO970326L publication Critical patent/NO970326L/no

2004-12-13 Publication of NO317730B1 publication Critical patent/NO317730B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 88
102000004169 proteins and genes Human genes 0.000 title claims abstract description 78
238000000034 method Methods 0.000 title claims abstract description 42
230000008569 process Effects 0.000 title claims abstract description 12
238000002360 preparation method Methods 0.000 title abstract description 6
239000000872 buffer Substances 0.000 claims abstract description 49
102000009618 Transforming Growth Factors Human genes 0.000 claims abstract description 5
108010009583 Transforming Growth Factors Proteins 0.000 claims abstract description 5
235000018102 proteins Nutrition 0.000 claims description 73
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 33
239000012634 fragment Substances 0.000 claims description 30
230000002829 reductive effect Effects 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 16
239000003960 organic solvent Substances 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
108010024636 Glutathione Proteins 0.000 claims description 6
-1 sulfhydryl compound Chemical class 0.000 claims description 6
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 claims description 4
102000005606 Activins Human genes 0.000 claims description 4
108010059616 Activins Proteins 0.000 claims description 4
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 4
102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 4
102000002746 Inhibins Human genes 0.000 claims description 4
108010004250 Inhibins Proteins 0.000 claims description 4
101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims description 4
239000000488 activin Substances 0.000 claims description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
235000018417 cysteine Nutrition 0.000 claims description 4
239000000893 inhibin Substances 0.000 claims description 4
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 3
229940099500 cystamine Drugs 0.000 claims description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 2
229960003180 glutathione Drugs 0.000 claims description 2
GXDPEHGCHUDUFE-UHFFFAOYSA-N sulfanylmethanol Chemical compound OCS GXDPEHGCHUDUFE-UHFFFAOYSA-N 0.000 claims description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 53
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 48
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
239000013612 plasmid Substances 0.000 description 29
150000001413 amino acids Chemical class 0.000 description 26
241000588724 Escherichia coli Species 0.000 description 25
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
240000004808 Saccharomyces cerevisiae Species 0.000 description 19
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 19
208000027418 Wounds and injury Diseases 0.000 description 19
206010052428 Wound Diseases 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 18
108020004414 DNA Proteins 0.000 description 17
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 12
239000002609 medium Substances 0.000 description 12
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000178 monomer Substances 0.000 description 11
239000008188 pellet Substances 0.000 description 11
239000007983 Tris buffer Substances 0.000 description 10
230000004071 biological effect Effects 0.000 description 10
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 9
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
239000000499 gel Substances 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000000523 sample Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000004007 reversed phase HPLC Methods 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
239000012506 Sephacryl® Substances 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000029087 digestion Effects 0.000 description 6
238000002955 isolation Methods 0.000 description 6
229930027917 kanamycin Natural products 0.000 description 6
229960000318 kanamycin Drugs 0.000 description 6
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
229930182823 kanamycin A Natural products 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
238000000746 purification Methods 0.000 description 6
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 6
229960000723 ampicillin Drugs 0.000 description 5
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000004166 bioassay Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
210000003000 inclusion body Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000000699 topical effect Effects 0.000 description 5
102000013563 Acid Phosphatase Human genes 0.000 description 4
108010051457 Acid Phosphatase Proteins 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000035876 healing Effects 0.000 description 4
229960002885 histidine Drugs 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
238000005063 solubilization Methods 0.000 description 4
230000007928 solubilization Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
239000013598 vector Substances 0.000 description 4
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
241000772415 Neovison vison Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
230000022159 cartilage development Effects 0.000 description 3
229960002433 cysteine Drugs 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000000539 dimer Substances 0.000 description 3
239000007862 dimeric product Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
239000000284 extract Substances 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000011164 ossification Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 2
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010051815 Glutamyl endopeptidase Proteins 0.000 description 2
108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 2
102100040892 Growth/differentiation factor 2 Human genes 0.000 description 2
101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
206010020649 Hyperkeratosis Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
208000002847 Surgical Wound Diseases 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
239000008051 TBE buffer Substances 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 2
101800000304 Transforming growth factor beta-2 Proteins 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
241000269370 Xenopus <genus> Species 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000019552 anatomical structure morphogenesis Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
230000003196 chaotropic effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000003837 chick embryo Anatomy 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000002710 gonadal effect Effects 0.000 description 2
239000003966 growth inhibitor Substances 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000005457 ice water Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000000921 morphogenic effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
210000000287 oocyte Anatomy 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
206010006802 Burns second degree Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
101100001670 Emericella variicolor andE gene Proteins 0.000 description 1
241000702189 Escherichia virus Mu Species 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241001622557 Hesperia Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000589538 Pseudomonas fragi Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
101100218949 Rattus norvegicus Bmp3 gene Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
244000247617 Teramnus labialis var. labialis Species 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
241000269368 Xenopus laevis Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000011759 adipose tissue development Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000010951 brass Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000037319 collagen production Effects 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
108010003914 endoproteinase Asp-N Proteins 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000000318 mullerian duct Anatomy 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000010915 one-step procedure Methods 0.000 description 1
230000001151 other effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000000819 phase cycle Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000030503 positive regulation of chemotaxis Effects 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000030788 protein refolding Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
125000002577 pseudohalo group Chemical group 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
230000022379 skeletal muscle tissue development Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000007447 staining method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19970326A 1994-07-25 1997-01-24 Fremgangsmate for fremstilling av dimerisk, biologisk aktivt TGF-beta-lignende protein NO317730B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94810439		1994-07-25
PCT/EP1995/002719 WO1996003433A1 (en)	1994-07-25	1995-07-12	New process for the production of biologically active protein

Publications (3)

Publication Number	Publication Date
NO970326D0 NO970326D0 (no)	1997-01-24
NO970326L NO970326L (no)	1997-01-24
NO317730B1 true NO317730B1 (no)	2004-12-13

Family

ID=8218293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19970326A NO317730B1 (no)	1994-07-25	1997-01-24	Fremgangsmate for fremstilling av dimerisk, biologisk aktivt TGF-beta-lignende protein

Country Status (19)

Country	Link
US (1)	US7057016B2 (zh)
EP (1)	EP0779896B1 (zh)
JP (2)	JPH11505404A (zh)
KR (1)	KR100394532B1 (zh)
AT (1)	ATE207934T1 (zh)
AU (1)	AU699879B2 (zh)
CA (1)	CA2194578A1 (zh)
DE (1)	DE69523611T2 (zh)
DK (1)	DK0779896T3 (zh)
ES (1)	ES2166402T3 (zh)
FI (1)	FI118385B (zh)
HU (1)	HU222829B1 (zh)
IL (1)	IL114702A (zh)
NO (1)	NO317730B1 (zh)
NZ (1)	NZ290374A (zh)
PT (1)	PT779896E (zh)
TW (1)	TW517059B (zh)
WO (1)	WO1996003433A1 (zh)
ZA (1)	ZA956139B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997023638A1 (fr) *	1995-12-21	1997-07-03	Ajinomoto Co., Inc.	Procede pour replier l'activine a humaine
DE10026713A1 (de) *	2000-05-30	2001-12-06	Walter Sebald	Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US20030134292A1 (en) *	2001-10-30	2003-07-17	Farchaus Joseph W.	Thermostable DNA polymerases and methods of making same
FR2871061B1 (fr) *	2004-06-04	2007-08-10	Coletica Sa	Principe actif capable d'induire la transformation du tgbf- latent inactif en tgfb actif
US7572474B2 (en) *	2005-06-01	2009-08-11	Mead Johnson Nutrition Company	Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) *	2008-10-24	2011-12-13	Mead Johnson Nutrition Company	Nutritional composition with improved digestibility
EP1966229B1 (en)	2005-09-12	2015-10-21	Abela Pharmaceuticals, Inc.	Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
US8435224B2 (en)	2005-09-12	2013-05-07	Abela Pharmaceuticals, Inc.	Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
US8480797B2 (en)	2005-09-12	2013-07-09	Abela Pharmaceuticals, Inc.	Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033082A2 (en)	2005-09-12	2007-03-22	Abela Pharmaceuticals, Inc.	Compositions comprising dimethyl sulfoxide (dmso)
GB0604966D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Medicaments and proteins
US8986769B2 (en)	2008-10-24	2015-03-24	Mead Johnson Nutrition Company	Methods for preserving endogenous TGF-β
BRPI0921494A2 (pt)	2008-11-03	2018-10-30	Prad Reasearch And Development Ltd	método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
JP5947721B2 (ja)	2009-10-30	2016-07-06	アベラファーマスーティカルズインコーポレイテッド	変形性関節症を治療するためのジメチルスルホキシド（ｄｍｓｏ）およびメチルスルホニルメタン（ｍｓｍ）製剤
US10647777B2 (en) *	2014-05-28	2020-05-12	Genzyme Corporation	Methods of controlling the formation of disulfide bonds in protein solutions
JP2016183118A (ja) *	2015-03-25	2016-10-20	東ソー株式会社	増殖因子前駆体のリフォールディング方法
WO2018122794A1 (en)	2016-12-30	2018-07-05	Biogend Therapeutics Co., Ltd.	Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof
TW202330579A (zh) *	2021-10-11	2023-08-01	高等教育聯邦系統匹茲堡大學	經工程改造TGF-β單體及使用方法
GB2616476A (en) *	2022-03-11	2023-09-13	Multus Biotechnology Ltd	Recombinant transforming growth factor beta 3 in yeast

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3168691D1 (en) *	1980-11-07	1985-03-14	Technicon Instr	Immunoassay of proteins
US4620948A (en)	1982-12-22	1986-11-04	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
GR79124B (zh)	1982-12-22	1984-10-02	Genentech Inc
ATE85080T1 (de)	1984-02-17	1993-02-15	Genentech Inc	Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en)	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en)	1985-02-22	1988-03-15	Monsanto Company	Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en)	1985-03-22	1991-07-18	Genentech Inc	Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en)	1985-03-29	1985-05-09	Creighton T E	Production of protein
EP0208539A3 (en)	1985-07-11	1988-08-03	Repligen Corporation	Folding disulfide-cross-linkable proteins
US5453363A (en)	1985-10-23	1995-09-26	Boehringer Mannheim Gmbh	Process for the activation of t-PA or Ing after genetic expression in prokaryotes
JPH0759598B2 (ja) *	1986-02-14	1995-06-28	藤沢薬品工業株式会社	ヒトインスリン様成長因子▲ｉ▼の製造法
NZ222168A (en)	1986-10-20	1991-05-28	Oncogene Science Inc	Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
NZ222569A (en)	1986-11-17	1990-08-28	Sandoz Ltd	Production of glioblastoma-derived t cell suppressor factor (g-tsf) using recombinant techniques
FI100106B (fi)	1986-12-05	1997-09-30	Novartis Ag	Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en)	1987-01-30	1990-06-05	Techne Corporation	Heterodimer form of transforming growth factor-beta
IL86090A (en)	1987-04-16	1993-03-15	Cetus Oncology Corp	Production of purified, biologically active, bacterially produced recombinant human csf-1
WO1988008849A1 (en)	1987-05-11	1988-11-17	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US5162507A (en)	1987-05-11	1992-11-10	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0293785A3 (en) *	1987-05-29	1990-05-02	Oncogen Limited Partnership	Cloning and expression of simian transforming growth factor-ss1
US4985544A (en)	1987-08-04	1991-01-15	Kyowa Hakko Kogyo Co., Ltd.	Process for renaturing fish growth hormone
US5061786A (en) *	1989-05-25	1991-10-29	Genentech, Inc.	Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5843463A (en) *	1990-12-21	1998-12-01	Antexbiologics, Inc.	Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5144006A (en) *	1991-06-13	1992-09-01	The Rockefeller University	Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors
US5407810A (en) *	1993-08-20	1995-04-18	Genentech, Inc.	Aqueous multiple-phase isolation of polypeptide
TW440566B (en) *	1994-07-25	2001-06-16	Novartis Ag	Novel process for the production of biologically active dimeric protein

1995
- 1995-07-11 TW TW084107189A patent/TW517059B/zh not_active IP Right Cessation
- 1995-07-12 PT PT95926858T patent/PT779896E/pt unknown
- 1995-07-12 DE DE69523611T patent/DE69523611T2/de not_active Expired - Lifetime
- 1995-07-12 ES ES95926858T patent/ES2166402T3/es not_active Expired - Lifetime
- 1995-07-12 HU HU9700211A patent/HU222829B1/hu not_active IP Right Cessation
- 1995-07-12 WO PCT/EP1995/002719 patent/WO1996003433A1/en active IP Right Grant
- 1995-07-12 KR KR1019970700477A patent/KR100394532B1/ko not_active IP Right Cessation
- 1995-07-12 NZ NZ290374A patent/NZ290374A/en not_active IP Right Cessation
- 1995-07-12 AT AT95926858T patent/ATE207934T1/de not_active IP Right Cessation
- 1995-07-12 DK DK95926858T patent/DK0779896T3/da active
- 1995-07-12 JP JP8505401A patent/JPH11505404A/ja not_active Withdrawn
- 1995-07-12 AU AU31096/95A patent/AU699879B2/en not_active Ceased
- 1995-07-12 CA CA002194578A patent/CA2194578A1/en not_active Abandoned
- 1995-07-12 EP EP95926858A patent/EP0779896B1/en not_active Expired - Lifetime
- 1995-07-24 ZA ZA956139A patent/ZA956139B/xx unknown
- 1995-07-24 IL IL11470295A patent/IL114702A/xx not_active IP Right Cessation
1997
- 1997-01-22 FI FI970258A patent/FI118385B/fi active IP Right Grant
- 1997-01-24 NO NO19970326A patent/NO317730B1/no not_active IP Right Cessation
2001
- 2001-03-20 US US09/813,271 patent/US7057016B2/en not_active Expired - Fee Related
2006
- 2006-11-09 JP JP2006304238A patent/JP4354980B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL114702A0 (en)	1995-11-27
WO1996003433A1 (en)	1996-02-08
IL114702A (en)	2005-03-20
JP2007082554A (ja)	2007-04-05
ES2166402T3 (es)	2002-04-16
ZA956139B (en)	1996-03-07
CA2194578A1 (en)	1996-02-08
HUT76667A (en)	1997-10-28
JPH11505404A (ja)	1999-05-21
FI118385B (fi)	2007-10-31
HU222829B1 (hu)	2003-11-28
EP0779896B1 (en)	2001-10-31
AU3109695A (en)	1996-02-22
DE69523611T2 (de)	2002-06-20
PT779896E (pt)	2002-03-28
US7057016B2 (en)	2006-06-06
NO970326D0 (no)	1997-01-24
NO970326L (no)	1997-01-24
FI970258A (fi)	1997-01-22
DK0779896T3 (da)	2002-02-18
DE69523611D1 (de)	2001-12-06
EP0779896A1 (en)	1997-06-25
NZ290374A (en)	1998-07-28
AU699879B2 (en)	1998-12-17
FI970258A0 (fi)	1997-01-22
US20020115834A1 (en)	2002-08-22
KR100394532B1 (ko)	2003-10-22
ATE207934T1 (de)	2001-11-15
JP4354980B2 (ja)	2009-10-28
TW517059B (en)	2003-01-11

Publication	Publication Date	Title
JP4354980B2 (ja)	2009-10-28	生物学的に活性なタンパク質の製造のための新規の方法
AU638075B2 (en)	1993-06-17	Process for the production of biologically active protein
JP2007031453A (ja)	2007-02-08	生物学的に活性な二量体型タンパク質の製造のための新規の方法
EP0542679A1 (en)	1993-05-19	Novel hybrid transforming growth factors

Legal Events

Date	Code	Title	Description
2012-02-20	MM1K	Lapsed by not paying the annual fees